Kornimate/medical-research-clean huggingface dataset:
a study to evaluate chronic hepatitis c infection in treatment experienced adults

Conditions: Chronic Hepatitis C Infection

Summary: the purpose of this study is to evaluate the safety and efficacy of abt-450, ritonavir and abt-267 (abt-450/r/abt-267; abt-267 also known as ombitasvir) and abt-333 (also known as dasabuvir) co-administered with ribavirin (rbv) in hepatitis c virus genotype 1 infected treatment-experienced adults.


Eligibility criteria:
inclusion criteria: * females must be post-menopausal for at least 2 years or surgically sterile or practicing specific forms of birth control. * chronic hepatitis c, genotype 1 infection and hcv rna level greater than 10,000 iu/ml at screening. * previous treatment failure of peg-interferon and ribavirin (pegifn and rbv). * no evidence of liver cirrhosis. exclusion criteria: * positive screen for drugs or alcohol. * significant sensitivity to any drug. * use of contraindicated medications within 2 weeks of dosing. * certain predefined abnormal laboratory tests. * positive hepatitis b surface antigen or anti-human immunodeficiency virus antibody.

Keywords: hepatitis c treatment-experienced null responder partial responder chronic hepatitis hepatitis c genotype 1 interferon-free hepatitis c virus relapser non responder viekira pak ombitasvir ribavirin ritonavir paritaprevir dasabuvir
effectiveness and feasibility of delivering an education program to patients with an acute exacerbation of copd

Conditions: Chronic Obstructive Pulmonary Disease With (Acute) Exacerbation

Summary: the purpose of this study is to determine if it is effective and feasible to provide a chronic obstructive pulmonary disease (copd) education program to patients admitted with an acute exacerbation of copd.

following an acute exacerbation of chronic obstructive pulmonary disease (aecopd) evidence strongly suggests that all patients should be discharged with an action plan, consisting of identified patient responsibilities for their ongoing care and advice on recognizing and seeking help in the event of future acute exacerbations. despite these recommendations, structured chronic obstructive pulmonary disease (copd) specific education is rarely offered within acute hospital settings and, in addition, research in this area is limited. this study aims to determine the effectiveness and feasibility of an introductory education program delivered during and shortly after an aecopd hospitalization.

Eligibility criteria:
inclusion criteria: * medically confirmed diagnosis of aecopd (alone or combined with other conditions) * capable of understanding the study information and giving informed consent exclusion criteria: * admitted due to lung diseases other than copd * received copd education in the previous 6 months (in primary care, acute or rehabilitation hospitals) * presence of diagnosis of dementia or incapacity to learn due to cognitive issues * have medical, cognitive or language limitations to communicating in written or spoken english * have participated or been asked to participate in the trial before * in the intensive care unit

Keywords: aecopd copd education
use of mini-fluid challenge for fluid responsiveness prediction during one-lung ventilation

Conditions: Acute Circulatory Failure During One-lung Ventilation Surgery

Summary: during thoracic surgery, an excessive use of fluid results in pulmonary complications. dynamic fluid responsiveness predictors are not easily usable during one lung ventilation. the investigators hypothesized that the assessment by transesophageal echocardiography (tee) of subaortic velocity time index (vti) variation after 100 ml of crystalloid would predict fluid responsiveness in patients receiving one-lung ventilation. this retrospective, observational, single center study was from january 2014 to december 2015. the investigators included 105 patients requiring one lung ventilation lung resection. the investigators analysed 39 patients presenting an acute circulatory failure. 100 ml of crystalloid was infused over 1-min. after an echocardiographic assessment at 1-min, remaining 400 ml were administered over 14-min fluid responsiveness was defined as an increase in the vti above 15% after infusion of 500 ml of crystalloid.


Eligibility criteria:
inclusion criteria: * lung resection * acute circulatory failure * one-lung ventilation exclusion criteria: * sinusal rhythm
lack of awareness of symptoms (anosognosia) in pd: an observational study for people with parkinson's

Conditions: Parkinson's; Anosognosia

Summary: anosognosia is a recognised condition for people with parkinson's, and is the result of physiological damage on brain structure. surgical parkinson disease nurse specialists have noticed that when reviewing the pre-surgery videos 12 months post-dbs, patients have forgotten and are shocked at how bad their symptoms were prior to surgery (personal communication), which may not be reflected in the change in qol reported. this lack of awareness, while possibly helpful in everyday life, may lead to effective treatments looking ineffective, or the benefits in qol of effective treatment appearing reduced. this confound may not only reduce the apparent effectiveness but also the related cost-effectiveness of treatment. as cost-effectiveness is determined by both size and longevity of an effect, current methods of capturing these data may be suboptimal.

the overarching aim of this project is to identify coping mechanisms and pathological lack of self-awareness and the impact they are likely to have on patient reported quality of life (qol) outcome measures for a chronic condition. this will be an observational study, a case series of approx. 10 to 20 patients. these patients will be recruited over a 6 month period from the queen elizabeth hospital, birmingham and will be informed of the study during their routine pre-surgical visit. patients will be eligible if they are about to undergo dbs at queen elizabeth hospital. if the participant has a carer, who is also willing to participate, they may also join the study. patients will be excluded if they are unable to complete questionnaires in english. once recruited and following consent, a patient will complete a brief battery of questionnaires both self-reported and clinician rated prior to surgery and at their 6 month post op visit.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of parkinson's as defined by the uk pds brain bank criteria exclusion criteria: * unable to complete questionnaires in english.

Keywords: parkinson's anosognosia dbs deep brain surgery
influence of regular exercise and detraining on metabolic and emotional parameters in diabetic individuals

Conditions: Diabetes Mellitus, Type 2

Summary: this quasi-experimental study aim to evaluate the effect of moderate aerobic exercise on glucose and lipid metabolism as well as the scales of anxiety and depression and levels of salivary cortisol in women with type 2 diabetes.

this quasi-experimental study aim to performed a 12-week training program (3 times/week, 60 minutes per session) which consisted of a supervised moderate aerobic exercise previously determined (50% to 70% of maximal heart rate) in women with type 2 diabetes.

Eligibility criteria:
inclusion criteria: * having normal physical examinations, * no participation in regular, moderate or intensive exercise for at least 6 months before the study and * not be following a diet exclusion criteria: * the use of insulin and beta-blocker medications and * the functional inability to perform exercise

Keywords: exercise exercise therapy diabetes mellitus, type 2
adaptive radiation treatment for head and neck cancer

Conditions: Head and Neck Cancer

Summary: this phase iii trial aims to: explore the impact of pre-treatment information and radiation dose redistribution on locoregional control in patients with locally advanced scchn. the dose to the primary tumor with margins, based upon pet and ct information, will be inhomogeneously increased to a tumor dose between 70 and 84 gy with decreasing dose towards the edges of the irradiated area. to determine the toxicity of combined modality treatment (cisplatin) with standard dose distribution versus combined modality treatment (cisplatin) with adaptive inhomogeneous radiation dose distribution.


Eligibility criteria:
inclusion criteria: * biopsy-confirmed squamous cell carcinoma of the oropharynx, oral cavity or hypopharynx * stage iii/iv, t3-4, nx m0 * \< 70 yrs * glomerular filtration rate (gfr) \>60 * who 0-1 * no previous malignancies except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix * adequate bone marrow function, adequate hepatic function,informed consent * \>18 years exclusion criteria: * expected failure from follow-up * previous malignancies except for adequately treated basal cell carcinoma of the skin and carcinoma in situ of the cervix * expected inability to complete either one of the treatment arms * pregnancy or lactation * patients (m/f) with reproductive potential not implementing adequate contraceptive measures * prior surgery, radiotherapy or chemotherapy for this tumor * contraindications or serious concomitant diseases preventing the safe administration of chemotherapy and/or radiotherapy or are likely to interfere with the study assessments * known active symptomatic fungal, bacterial and/or viral infections including hiv * concomitant (or with 4 weeks before randomisation) administration of any other experimental drug * concurrent treatment with any other anti-cancer therapy * prior treatment with one or more of the active compounds

Keywords: advanced head and neck cancer adaptive radiotherapy cisplatinum
a study of bms-986195 in healthy male subjects

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to investigate the effects bms-986195 in healthy male subjects.


Eligibility criteria:
for more information regarding bristol-myers squibb clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * male subjects, if not surgically sterilized, must agree to use adequate contraception * body mass index (bmi) of 18.0 to 32.0 kg/m2, inclusive (bmi = weight \[kg\]/\[height (m)\]2), and total body weight \>50 kg * all prescribed medication, including live vaccinations, must have been stopped at least 30 days prior to admission to the clinical research center * all over-the-counter (otc ) medication, vitamin preparations and other food supplements, or herbal medications (eg, st. john's wort) must have been stopped at least 14 days prior to admission to the clinical research center * ability and willingness to abstain from alcohol, methylxanthine-containing beverages or food (coffee, tea, cola, chocolate, energy drinks), and grapefruit (juice) from 3 days prior to admission to the clinical research center * good physical and mental health on the basis of medical history, physical examination, clinical laboratory, ecg and vital signs, as judged by the principal investigator exclusion criteria: * previous participation in the current study * known previous exposure to bms-986195 * employee of pra or the sponsor * history of relevant drug and/or food allergies, including allergy to immunologic or related compounds or allergy to seafood or marine products * using tobacco products within 60 days prior to drug administration * positive screen for hepatitis b surface antigen (hbsag), anti-hepatitis c virus (hcv) antibodies or anti-human immunodeficiency virus (hiv) 1 and 2 antibodies other protocol defined inclusion/exclusion criteria could apply
the effect of povidone-iodine ophthalmic surgical prep solution on respiration in children undergoing strabismus surgery with general anesthesia.

Conditions: Strabismus

Summary: determine whether the application of povidone-iodine ophthalmic solution onto the ocular surface causes a change in respiration in children undergoing strabismus surgery with general anesthesia. hypothesis: the application of povidone-iodine ophthalmic solution to the ocular surface causes a change in respiration in children during general anesthesia prior to strabismus surgery.

the study is randomized and single blind. one hundred children were randomly assigned to have either povidone-iodine (group a) or balanced salt solution (bss) (group b) eye drops instilled into their eyes during anesthesia just prior to strabismus surgery. after induction of anesthesia and insertion of an lma while the patient was at a steady state of anesthesia and spontaneously breathing sevoflurane in oxygen, 3 drops of either povidone-iodine or bss was instilled into each eye (right eye first). respiratory rate was determined by measuring the peak-to-peak interval on the capnograph. this is similar to calculating heart rate by measuring the r-r interval on an ecg. hr, bp, sao2, etco2, and expired sevoflurane were measured in each patient. medical history information collected included history of prior surgeries, co-existing diseases, or apnea. appropriate statistical analyses were performed for comparisons between the groups with respect to respiratory rate, hr, bp, expired sevoflurane, and co-existing diseases.

Eligibility criteria:
* inclusion criteria * children between the ages of 1 year and 17 years * scheduled for strabismus surgery * anesthesia plan includes inhalational induction with sevoflurane and the use of a laryngeal mask airway (lma) with spontaneous ventilation, per the attending anesthesiologist. exclusion criteria * history of an adverse reaction to iodine * history of any thyroid disease * patients who require tracheal intubation, as determined by the attending anesthesiologist; e.g. craniofacial anomalies. * patients with a contraindication to sevoflurane, such as malignant hyperthermia or severe left ventricular dysfunction. * inability or unwillingness of the subject or legal guardian/ representative to give informed consent.
graphene photothermal adjuvant therapy for mild corona virus disease 2019: a prospective randomized controlled trial

Conditions: COVID-19

Summary: this is a future-proof and randomized controlled clinical study on the clinical efficacy of graphene photothermal adjuvant therapy in corona virus disease 2019(covid-19) patients with mild symptoms. the objective is to examine the effect of graphene photothermal adjuvant therapy on the time line for such corona virus disease 2019 patients to achieve a negative severe acute respiratory syndrome coronavirus 2 (sars-cov-2) nucleic acid test result, and their duration of disease. patients who meet study criteria will be randomized into the grapheme adjuvant therapy combined with conventional therapy group (treatment group) and the conventional therapy only group (control group). contrasted to the control groups, the treatment groups will undergo 30-min of graphene adjuvant therapy every day for 7 d.

following enrollment, patients will be randomized into treatment or control groups. all groups will receive the same conventional therapy. in addition, treatment groups will undergo graphene adjuvant therapy 30 minutes per day for 7 d. upon completion of the treatment protocol, specific study endpoints will be compared between the treatment and control groups.

Eligibility criteria:
inclusion criteria: * meet the diagnostic criteria for mild covid-19. * patients aged 18-60 years (inclusive). * no later than 48 h after testing positive and the onset of clinical symptoms * sign informed consent form. exclusion criteria: * severe or critically patients with covid-19. * resting heart rate over 120 beats per minute. * coronary heart disease patients with acute cardiac insufficiency. * acute exacerbation of chronic obstructive pulmonary disease（copd）. * uncontrolled hypertension \[resting systolic blood pressure(sbp) more than 180 mmhg and diastolic blood pressure(dbp) more than 90 mmhg\]; uncontrolled diabetes(random plasma glucose, rpg\>16.7mmol/l, hba1c\>7.0%) * patients with severe cardiovascular, hepatic, renal and hematopoietic diseases. * pregnant or menstruating woman. * known or suspected history of active tuberculosis or extrapulmonary tuberculosis, patients with brucellosis, pneumonia-related illness from other causes * covid-19 patients for the second or more times * those who cannot cooperate due to various reasons * body temperature: more than 38℃.

Keywords: corona virus disease 2019 randomized control trial adjuvant therapy graphene photothermal
a study to evaluate the effectiveness of vizamyl™ reader training programme in europe

Conditions: Cognitive Impairment

Summary: this is a study to determine the effectiveness of the vizamyl™ reader training programme in clinical practice in europe

this study is a combination of prospective and retrospective models.

Eligibility criteria:
inclusion criteria: * the subject is an adult (aged 18 years or older) of any race or gender and has been referred for a vizamyl™ pet brain scan as part of the assessment of his/her cognitive impairment. * the vizamyl™ scan was ordered as part of the clinical care of the subject and is not exclusively for a clinical trial. * if informed consent is required by the local iec, the subject, or his/her legally authorised representative, is willing and able to sign consent for use of their de-identified vizamyl™ pet images and associated anatomic images (brain ct and/or mri) used in the interpretation of the vizamyl™ images as well as de-identified demographic information. exclusion criteria: * if informed consent is required by the local iec, the subject (or representative) is not willing to consent to their de-identified images and other data being used in this study.

Keywords: vizamyl flutemetamol alzheimer's disease cognitive impairment dementia
safety and efficacy of "immuncell-lc" in tace therapy

Conditions: Carcinoma, Hepatocellular

Summary: to evaluate the efficacy and safety of 'immuncell-lc group' and 'non-treatment group' in the patients undergone transarterial chemoembolization for intermediate stage hepatocellular carcinoma

ilc-iit-05 is randomized, open-label, multi-center phase 2 clinical trial. to confirm clinical efficacy and safety between 'immuncell-lc group' and 'non-treatment group', primary outcome, recurrence free survival(rfs) will be evaluated. for secondary outcome, overall survival(os), changes of alpha feto protein(afp), correlation of between myeloid-derived suppressor cell change and prognosis, adverse event, ecog-ps and hematological examination will be evaluated.

Eligibility criteria:
inclusion criteria: * patients who have consented to the study by providing signature of self * patients who are more than 20 and less than 80 years old * child-pugh class should be a(score 5-6) or b(score 7-8) * ecog performance status (ecog-ps) score is less than 1 or equal to * patients who have been diagnosed with bclc stage b hepatocellular carcinoma by pathological/radiological test(dynamic contrast-enhanced ct or dynamic mri) and tumor removal has been confirmed after tace (when patients have been diagnosed with recurrence of hepatocellular carcinoma after surgery or local treatment, if conditions are same as above, patients could be included) * patients who satisfy the following conditions of the blood test and kidney, liver function test * absolute neutrophil count \> 500/µl * hemoglobin ≥ 8.5 g/dl * platelet count \> 50,000/µl * blood creatinine ≤ 1.5xupper normal limit * total bilirubin \< 3mg/dl * albumin ≥ 2.8g/dl exclusion criteria: * patients who have been confirmed with residual tumor or extrahepatic metastases * patients who have lymph node metastases or portal vein, hepatic vein invasion * patients who have a history of treatments or are in conditions as below * liver transplantation * from informed consent form sign date, systemic chemotherapy in 4 weeks or ongoing adverse drug reactions from anticancer drug in 6 weeks * external beam radiation, immunotherapy, molecular target therapy * more than 2 times of systemic chemotherapy * biliary reconstruction or endoscopic biliary treatment * patients who have a history of auto-immune diseases (ex. rheumatoid arthritis, systemic lupus erythematosus, vasculitis, multiple sclerosis, adolescent insulin-dependent diabetes mellitus, etc.) * patients who have a history of malignant tumors in the recent 5 years prior to the study except hepatocellular carcinoma * patients who participated in another clinical trial and conducted treatment in 4 weeks or have a plan for administration of another clinical trial treatment since informed consent form sign date * patients who have uncontrollable or serious disease * pregnant women or nursing mother * patients who intend to get pregnant during the study

Keywords: immuncell-lc transarterial chemoembolization
prognostic value related to the presence of thrombosis or portal vein invasion in patients with hepatocellular carcinoma submitted to surgery

Conditions: Hepatocellular Carcinoma; Portal Vein Thrombosis; Hepatic Portal Vein Tumor Invasion

Summary: a retrospective study based on analysis of medical records of patients with hepatocellular carcinoma treated at the hospital sírio-libanês (sao paulo-brazil) between 2001 and 2011 with diagnosis confirmed by imaging or histological specimen underwent surgical resection with curative intent. the study aims to determine the prognostic value of vascular complications related to cancer and to evaluate the survival rate of these patients, comparing the data with those reported in the literature.


Eligibility criteria:
inclusion criteria: * hepatocellular carcinoma confirmed by imaging or histological specimen underwent surgical resection, with or without hepatic cirrhosis association; * presence of venous outflow obstruction, either by direct tumor invasion or thrombosis, on portal vein or one of its main vessels; exclusion criteria: * patients undergoing prior systemic treatment; * patients presenting incomplete data that do not allow their classification according to the stratification models; * patients whose information of progression or death can not be recovered;

Keywords: hepatocellular carcinoma thrombosis portal vein invasion
inflammation and organ impact during hepatic surgery

Conditions: Hepatic Surgery

Summary: monitoring of inflammatory substances (such as interleukins, crp, albumine), and markers of organ dysfunction (such as creatinine, proenkephaline, amylase, troponine, ifabp and lactate) during elective liver resection. the study also includes monitoring of hemodynamic parameters, blood loss and postoperative complications. results are to be used för power calculation for future trials.

during hepatic surgery, blood and urine samples will be obtained at 3 times during surgery, at 3 h after resection of liver, at 24 h after resection of liver and at post operative day 2, and subsequntly analyzed for the above mentioned substances. routine labs will be monitored until patient is discharged from hospital. during surgery, hemodynamic parameters will be monitored by picco calculations. urine output and blood loss will be registred.

Eligibility criteria:
inclusion criteria: asa i-iii patient has given informed consent to participate in study. exclusion criteria: preoperative kidney failure (e-gfr \>30), current infection treatment with corticosteroids coagulopathy surgical or anatomical conditions that makes patient unsuitable for participation (for example reoperation, need of vascular bypass, single tumor)

Keywords: liver surgery hepatic resection inflammation organ dysfunction blood loss ifabp